Related references
Note: Only part of the references are listed.The epilepsy-autism spectrum disorder phenotype in the era of molecular genetics and precision therapy
Nicola Specchio et al.
EPILEPSIA (2022)
Subependymal giant-cell astrocytoma: A surgical review in the modern era of mTOR inhibitors
G. Danassegarane et al.
NEUROCHIRURGIE (2022)
Advances in the genetics and neuropathology of tuberous sclerosis complex: edging closer to targeted therapy
Paolo Curatolo et al.
LANCET NEUROLOGY (2022)
Congenital subpendymal giant cell astrocytoma in children with tuberous sclerosis complex: growth patterns and neurological outcome
Denise L. Chan et al.
PEDIATRIC RESEARCH (2021)
Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile
Krinio Giannikou et al.
MODERN PATHOLOGY (2021)
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations
Hope Northrup et al.
PEDIATRIC NEUROLOGY (2021)
Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis - Final Results From the EMINENTS Study
Katarzyna Bobeff et al.
FRONTIERS IN NEUROLOGY (2021)
Mortality in tuberous sclerosis complex
Shridhar Parthasarathy et al.
EPILEPSY & BEHAVIOR (2021)
The coding and non-coding transcriptional Iandscape of subepenaymal giant cell astrocytomas
Anika Bongaarts et al.
BRAIN (2020)
Neurosurgical treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex: a series of 44 surgical procedures in 31 patients
Flavio Giordano et al.
CHILDS NERVOUS SYSTEM (2020)
Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA)
Daniel Ebrahimi-Fakhari et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)
Danielle R. Weidman et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis
Paolo Frassanito et al.
CHILDS NERVOUS SYSTEM (2020)
Progression of Fetal Brain Lesions in Tuberous Sclerosis Complex
Antoinette Bernabe Gelot et al.
FRONTIERS IN NEUROSCIENCE (2020)
Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex
Anna C. Jansen et al.
FRONTIERS IN NEUROLOGY (2019)
Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study
Anna C. Jansen et al.
FRONTIERS IN NEUROLOGY (2019)
What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods
Konrad Stawiski et al.
MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE (2017)
TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients
John C. Kingswood et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Everolimus Alleviates Obstructive Hydrocephalus due to Subependymal Giant Cell Astrocytomas
Romina Moavero et al.
PEDIATRIC NEUROLOGY (2017)
Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations
Anika Bongaarts et al.
ONCOTARGET (2017)
Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex
Tao Jiang et al.
WORLD NEUROSURGERY (2017)
Systemic effects of treatment with mTOR inhibitors in tuberous sclerosis complex: a comprehensive review
K. Sadowski et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Management of side effects of mTOR inhibitors in tuberous sclerosis patients
Krzysztof Sadowski et al.
PHARMACOLOGICAL REPORTS (2016)
Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
David N. Franz et al.
PLOS ONE (2016)
mTOR inhibitors and diabetes
Bruno Verges et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma
Monika Siedlecka et al.
FOLIA NEUROPATHOLOGICA (2015)
Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report
Thomas L. Beaumont et al.
JOURNAL OF NEUROSURGERY-PEDIATRICS (2015)
Factors Affecting Response to Everolimus Therapy for Subependymal Giant Cell Astrocytomas Associated With Tuberous Sclerosis
Joanna Trelinska et al.
PEDIATRIC BLOOD & CANCER (2015)
Mechanistic Target of Rapamycin (mTOR) in Tuberous Sclerosis Complex-Associated Epilepsy
Paolo Curatolo
PEDIATRIC NEUROLOGY (2015)
Tuberous Sclerosis Complex: A Survey of Health Care Resource Use and Health Burden
Anne M. Rentz et al.
PEDIATRIC NEUROLOGY (2015)
Natural History and Current Treatment Options for Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex
Sergiusz Jowiak et al.
SEMINARS IN PEDIATRIC NEUROLOGY (2015)
Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex
Katarzyna Kotulska et al.
CHILDS NERVOUS SYSTEM (2014)
Surgical Treatment of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex Patients
Katarzyna Kotulska et al.
PEDIATRIC NEUROLOGY (2014)
Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): Clinical recommendations
Sergiusz Jozwiak et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2013)
Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Katarzyna Kotulska et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2013)
Everolimus for Tumor Recurrence After Surgical Resection for Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex
David Neal Franz et al.
JOURNAL OF CHILD NEUROLOGY (2013)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis, Complex Consensus Conference 2012
Jonathan Roth et al.
PEDIATRIC NEUROLOGY (2013)
Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Romina Moavero et al.
ITALIAN JOURNAL OF PEDIATRICS (2013)
Advances in the management of subependymal giant cell astrocytoma
Thomas L. Beaumont et al.
CHILDS NERVOUS SYSTEM (2012)
mTOR Inhibitors in Tuberous Sclerosis Complex
Paolo Curatolo et al.
Current Neuropharmacology (2012)
Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex
Marta Perek-Polnik et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2012)
Early control of seizures improves long-term outcome in children with tuberous sclerosis complex
Roberta Bombardieri et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2010)
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis.
Darcy A. Krueger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature
M. E. A. P. M. Adriaensen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Subependymal giant-cell astrocytomas in pediatric tuberous sclerosis disease: When should we operate?
Sandrine de Ribaupierre et al.
NEUROSURGERY (2007)
A case of solitary subependymal giant cell astrocytoma - Two somatic hits of TSC2 in the tumor, without evidence of somatic mosaicism
T Ichikawa et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2005)
Rapid regrowth of solitary Subependymal giant cell astrocytoma - Case report
K Yamamoto et al.
NEUROLOGIA MEDICO-CHIRURGICA (2002)
Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs
SL Dabora et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Share Paper
